139 results about "Diabetic renal disease" patented technology

The invention discloses a Chinese herbal extract for treating diabetic nephropathy and a preparation method thereof. The Chinese herbal extract is prepared from 600 to 1000 parts by weight of Radix Astragali, 400 to 600 parts by weight of Gorgon fruit, 400 to 600 parts by weight of Cherokee rose-hip, 600 to 1000 parts by weight of Common achyranthes herb, 400 to 480 parts by weight of Ligustrum lucidum, 400 to 480 parts by weight of Ramulus Euonymi, and 320 to 480 parts by weight of Rheum officinale. Based on internationally unified clinical diagnostic criteria of diabetic nephropathy (DN), Compound particles of the Chinese herbal extract are carried out a comparison with Lotensin according to a randomized control principle through a contrast observation on 300 diabetic nephropathy patients taking respectively the compound particles and Lotensin, and a comparison result shows that 1) the compound particles can improve clinical symptoms of DN patients; and 2) the compound particles canreduce obviously urinary albumin in a DN early stage and urinary protein in a DN clinical stage, protect kidney functions and prevent effectively a development of early stage DN. Based on the prescribed curative effect evaluation criterion, a total effective rate of a Chinese herbal compound particle group is 86.7% and is obviously superior to that of a comparison group.

The invention belongs to the field of biology and medicine examination, and relates to a method for a protein spectrum of differential expression in a type 2 diabetes serum sample. The method comprises the following steps: adopting a surface-enhanced laser desorption / ionization time-of-flight mass-spectrometric technique to screen whole protein fingerprint of a diabetes chronic complication serum sample, using a data mining technique to screen biological labels in the fingerprint, establishing an analytic decision tree model of N serum protein components, and displaying that the type 2 diabetic nephropathy patient has the difference of the serum protein fingerprint as a result through blind verification and enlarged sample verification models. The method possibly provides reference information for further diagnosis and pathogenesis of diabetic nephropathy, provides research basis and new target for studying molecular mechanism formed by the diabetic nephropathy, and can further be used for guiding drug development and curative effect analysis.

The diabetes treating and nephrosis medicine is prepared with 7 kinds of Chinese medicinal materials including astragalus root, sealwort, dogwood, leech, Chuanxiong rhizome, etc. The preparation process is also disclosed. The medicine of the present invention has the functions of benefiting vital energy, promoting blood circulation, nourishing Yin and kidney, and is suitable for treating diabetes caused by deficient vital energy and Yin and meridian stasis and nephrosis. Clinical application shows that it has fast and obvious treating effect and no bad reaction.

The invention discloses a medicine composition for treating diabetic nephropathy. The prepared medicine composition comprises the following main medicine effect raw materials in parts by weight: 300 to 400 parts of astragalus mongholicus, 200 to 300 parts of prepared rehmannia root, 100 to 200 parts of dogwood, 200 to 300 parts of salvia miltiorrhiza, 50 to 150 parts of monkshood, 200 to 300 parts of poria cocos, 50 to 150 parts of Chinese yam, 100 to 200 parts of ligusticum wallichii, 100 to 200 parts of angelica sinensis, 50 to 150 parts of curcuma zedoary and 200 to 300 parts of leonurus. A preparation method of the medicine composition comprises the steps that: all medicine effect raw materials are weighed according to the recipe and are uniformly mixed through pulverization, water extraction concentration or a pulverization and water extraction concentration combination mode, and the medicine composition is prepared. The medicine composition disclosed by the invention can warm the kidney, strengthen the spleen, activate the blood and promote the diuresis, and is used for patients in the clinical stage of the diabetic nephropathy and patients with the symptoms of deep thready pulse, white fur, dark tongue nature, slight face and double lower limb edema, anorexia and loose stool, sallow complexion or paleness, no luster, dizziness insomnia and lassitude caused by spleen andkidney deficiency and collaterals stasis resistance.

The invention provides a test paper for semi-quantitatively detecting colloid selenium in microdose albumin in urine. The test paper can be applied in the fields of early diagnosis of diabetic nephropathy, hypertensive nephropathy and preeclampsia and injury of kidney caused by various poisonous substances. A plastic bottom plate of the test paper is orderly glued with a sampling liquid absorption part, a colloid selenium labeling part, a detection reaction part and a water absorption part, wherein the colloid selenium labeling part is a single-cloning antibody 1 which is coated by a glass fiber membrane, or acetic acid fiber membrane, or nylon membrane and labeled by the colloid selenium; the detection reaction part is a nitrocellulose membrane which is provided with two detection bands and quality control bands, T1 is a single-cloning antibody 2 which is precisely quantitative, and T2 is the single-cloning antibody 2 with a certain concentration; and the quality control bands are coated by antiplague IgG. The invention provides a method for semi-quantitatively detecting the microdose albumin in a urine sample conveniently, visually and quickly.

The invention provides a diabetic nephropathy-non-diabetic nephropathy differential diagnosis device and relates to the biological detection technology field. Defects that a standard in a traditionalchronic kidney disease clinical practice guide (KDOQI) is not objective and unified and is not suitable for serving as a diagnosis standard, and a traditional kidney puncture biopsy technology is large in trauma, can cause complications after operation and is high in technical difficulty. In a diabetic nephropathy-non-diabetic nephropathy differential diagnosis process provided in the invention, anew index is selected by adopting a machine learning method to construct a diabetic nephropathy and non-diabetic nephropathy differential diagnosis model, pain of a patient can be reduced, a diagnosis result is accurate, an application range is wide, and a good auxiliary diagnosis effect is provided for clinical practice.

The invention discloses a traditional Chinese medicine for treating diabetic nephropathy and a preparation method thereof. The traditional Chinese medicine for treating diabetic nephropathy contains astragalus mongholicus, bighead atractylodes rhizome, cartialgenous, cinnamon, rhizome dioscoreae, codonopsis pilosula, poria cocos, fructus lycii, flatstem milkvetch seed, tortoise shell, rehmannia, dogwood, angelica sinensis, ligusticum wallichii, salvia miltiorrhiza, earthworm, ramulus mori and moutan bark. The traditional Chinese medicine has functions of warming yang, nourishing qi and invigorating spleen and kidneys, and has definite effect for patients with weak spleen and the kidneys. The traditional Chinese medicine is prepared from natural vegetable drugs; and the components are pure Chinese medicines, accord with the theory of traditional Chinese medicine and are harmless to the human body. The traditional Chinese medicine can be taken orally and is convenient to use.

The invention relates to a method for preparing salvia miltiorrhizae phenolic acid and its new application in medicine production field. The method comprises following steps: adding water or alcohol into salvia miltiorrhizae for extraction, purifying phenolic acid through column chromatography and purification; washing with alcohol solution, condensing washing solution; adjusting pH, extracting with organic solvent, condensing and drying, getting salvia miltiorrhizae phenolic acid with salvia miltiorrhizae phenolic acid A and B content being above 90%. It is proven by medical effect and pharmacological research that the salvia miltiorrhizae phenolic acid can be used to prepare medicine that treats type-2 diabetes and its complication, including diabetes kidney disease, hepatic disease, and blood rheological property change caused by diabetes. It is tested that the effect of salvia miltiorrhizae phenolic acid and its preparation is strong, and they are safe medicine.

Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for the prevention and / or treatment of for preventing or treating a renal disorder complication. The invention further relates to methods, compounds and compositions for the prevention and / or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in diabetic patients.

The invention provides a traditional Chinese medicine composition for treating diabetic nephropathy. The traditional Chinese medicine composition comprises the following components of Ramulus euonymi, trichosanthes root, Panax pseudo-ginseng var. notoginseng and rhizoma coptidis according to the proportion by weight of 1-3:1-2:1-2:1-3. When being taken, the four medicines are respectively smashed and mixed, decocted by a traditional Chinese medicine decocting method and filtered, and the filtered liquid medicine is taken.

The present invention provides drugs containing chymase inhibitors as active ingredients for improving glucose intolerance or preventing and / or treating diseases caused by glucose intolerance. The diseases caused by glucose intolerance are diabetes and / or diabetes complications, wherein the diabetes complications include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinism, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, angitis, stroke, hypertension, renal insufficiency, nephropathy, nephritis, renal artery aneurysm, renal infarction, obesity and the like.

The invention provides a traditional Chinese medicine composition for treating diabetic nephropathy with spleen and kidney deficiency. 300. Sunburn Epimedium 50-250, Echeveria 100-300, Salvia miltiorrhiza 50-250, Salt Plantago 50-200, and medicinal excipients. At the same time, it provides a preparation method of a traditional Chinese medicine composition for treating diabetic nephropathy with spleen and kidney deficiency, which is used for treating diabetic nephropathy. The effect of the present invention is that the traditional Chinese medicine composition overcomes the disadvantages of traditional dosage forms such as decoction, adopts the method of water extraction, retains the active ingredients with clinical curative effect in the composition, and adopts high-efficiency dynamic circulation extraction equipment to extract the active ingredients to the greatest extent , to ensure its clinical efficacy. The preventive and therapeutic effects on diabetic nephropathy with both spleen and kidney deficiency are obviously better than similar drugs.

Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.

The invention relates to new application and a new action mechanism of verbascoside, in particular to application of verbascoside in the drugs for treating and preventing type II diabetic nephropathy,and the research on the protection function of the verbascoside for the type II diabetic nephropathy and the action mechanism thereof. Results show that the verbascoside can alleviate liver injury caused by high glucose and lower the serum creatinine, urea nitrogen and urinary microalbuminuria levels, the blood fat level (total cholesterol and triglyceride) and the fasting blood-glucose and bloodinsulin level of spontaneous diabetes db / db mice; TGF (Transforming Growth Factor)-beta 1 and the signal transduction protein Smad3 and Smad4 and alpha-SMA protein expression thereof in a kidney tissue are obviously lowered; meanwhile, the verbascoside can alleviate the liver injury caused by high glucose; HK-2 proliferation and EMT (pithelial-Mesenchymal Transition) formation can be inhibited. In conclusion, the verbascoside has an obvious protection function on the type II diabetic nephropathy, the action mechanism of the verbascoside is that the kidney protection function of the verbascoside is implemented through oxidative stress reaction regulation and control, TGF-beta / smad signaling channel inhibition and kidney fibrosis alleviation.

The invention provides an application of a Aspidopterys obcordata Hemsl. extract in preparation of a medicine for preventing and / or treating diabetic nephropathy. The medicine for preventing and / or treating diabetic nephropathy provided by the invention takes the Aspidopterys obcordata Hemsl. extract as an active component, and the medicine can be prepared into any dosage form together with pharmaceutically common auxiliary materials. The Aspidopterys obcordata Hemsl. extract can relieve kidney injury and inhibit proliferation of fibroblasts at a high glucose level, has the effect of resisting renal interstitial fibrosis, has no obvious cytotoxicity to normal tissue cells, and has good application prospect in treatment of diabetic nephropathy.

A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt / V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other / unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng / L (IQR, 2.4 to 14.0 ng / L). n-oxPTH concentrations were not different in men and women (5.9 ng / L; IQR, 2.4 to 14.2 ng / L; n=224; vs. 5.5 ng / L; IQR, 2.4 to 14.0 ng / L; n=1 16; p=0.915).

The invention relates to a pure traditional Chinese medicine preparation for treating glomerular diseases. The pure traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 30 parts of membranous milkvetch root, 12 parts of amur corktree bark, 15 parts of rhubarb, 40 parts of glabrous greenbrier rhizome, 20 parts of radix salviae miltiorrhizae, 15 parts of oriental waterplantain rhizome, 20 parts of epimedium herb, 15 parts of lalang grass rhizome and 30 parts of motherwort herb, and prepared by decoction, filtration, concentration of filtrate and drying. The pure traditional Chinese medicine preparation has significant efficacy for kidney diseases comprising acute and chronic glomerulonephritis, nephrotic syndrome, hypertensive nephropathy, diabetic nephropathy and early renal insufficiency caused by various reasons; furthermore, the raw materials are easily available, the production process is simple, the toxicity and side effects are small, and the administration is convenient, thereby providing the effective pure traditional Chinese medicine preparation for treating the kidney diseases.

The invention relates a medicinal composition containing Gliquidone, taurine and its medicinal salts, and the use of the composition in preparing medicament for the treatment of diabetes, the treatment and / or prevention of renal disease complication related to type II diabetes. The composition comprises Gliquidone 10-180mg, taurine and its medicinal salts 0.5-10g, and pharmaceutically acceptable carrying agents.

The invention relates to a Chinese medicinal composition for treating diabetic nephropathy. The Chinese medicinal composition is prepared from the following Chinese medicinal decoction pieces in parts by weight: 15-25 parts of astragalus, 7-13 parts of cherokee rose fruit, 7-13 parts of Szechuan lovage rhizome, 10-20 parts of sunset abelmoschus flower, 2-8 parts of rhubarb, 7-13 parts of kudzuvine root and 10-20 parts of common achyranthes herb. An oral preparation of the traditional Chinese medicine is prepared by the following steps: extracting the astragalus, the Szechuan lovage rhizome, the sunset abelmoschus flower and the kudzuvine root by using ethanol; collecting an extracting solution and concentrating into clear paste of which the relative density is 1.08-1.15; extracting together with the cherokee rose fruit, the rhubarb and the common achyranthes herb by using water; collecting an extracting solution and concentrating to clear paste of which the relative density is 1.08-1.5; mixing the two clear pastes; continually concentrating into thick paste of which the relative density is 1.30-1.40; adding auxiliary materials to obtain a dosage form suitable for clinical application. A prepared Chinese medicinal oral preparation has the advantages of high extraction efficiency of effective components, stable content, good medicinal effect, low dosage and easiness in preparation and formulation.

The invention relates to a traditional Chinese medicine preparation for treating diabetic nephropathy and preparation and administration methods thereof. The traditional Chinese medicine preparation is prepared from the following raw materials: astragalus membranaceus, radix pseudostellariae, semen cuscutae, cornus officinalis sieb et zucc, bighead atractylodes rhizome, the root of kudzu vine, gorgon fruit powder, fructus rosae laevigatae powder, periostracum cicada powder, eupatorium powder, agastache rugosus powder, rheum officinale powder, scutellaria baicalensis powder, radix rehmanniae recen, pseudo-ginseng powder and salviae miltiorrhizae. According to the theory of traditional Chinese medicine, treatment determination based on syndrome differentiation is performed by combining features of incidence of diabetic nephropathy and the condition of kidney injury, so that a traditional Chinese medicine compound preparation is formulated; through long-term clinical observation, the clinical symptoms of a patient are improved, proteinuria, urea nitrogen and serum creatinine are decreased to different extents, development of nephropathy is delayed, the renal function is improved, and the preparation plays a role of treating both symptoms and root causes.

The invention relates to the application of cornuside in preparing pharmaceuticals used for curing diabetic nephropathy. The invention raises a novel application of cornuside in preparing pharmaceuticals used to cure diabetic nephropathy and provides a novel pharmaceutical choice for curing diabetic nephropathy. Through experimental verification, 0.1g-5.5g / kg dosage of cornuside has remarkable effects in curing diabetic nephropathy. Cornuside has satisfying effects of anti-inflammatory damage and improving renal function on renal tissue under the condition of diabetes, and is effective pharmaceutical in curing diabetic nephropathy.

The invention relates to the field of a drug, and provides a preparation method of a Korean drug extract for preventing and treating diabetic nephropathy. The method comprises the following steps: ethanol extraction, refining by an adsorption clarification method and purifying with a macroporous resin column. Compared with the prior art, by limiting the elution condition, the effective substance content proportion in the Korean drug extract is adjusted, the flavonoid substance content such as monarch drug component Puerarin is obviously increased, and the treatment effect of the Korean drug extract is increased. The invention provides the Korean drug extract obtained by the above preparation method, and the mass ratio of general flavone, total polysaccharide and total saponin in the Koreandrug extract is 5-15:1-3:1-4. The active ingredient ratio in the Korean drug extract is reasonable, and the blood sugar reduction and kidney protection effects are obvious. The Korean drug tablets containing the Korean drug extract has the advantages of small administration amount and convenient carrying. The Korean drug extract or the Korean drug tablets can be used as the drug for preventing and treating diabetic nephropathy.

The invention discloses a significant position extracted from hydrangea paniculata sieb and the method for producing it, medical compounds containing such position, and the usage of it, especially in producing drugs for preventing and / or curing kidney incompetence, high blood pressure and diabetes, kidney disease.

The invention discloses a detection kit and a detection method for diabetic kidney diseases. The detection kit comprises a plate sealing film; a sealing the bag; an enzyme-labeled coating plate; a standard substance: 2700 ng / L; a standard substance diluent; an enzyme-labeled reagent; a sample diluent; a color developing agent solution A; a color developing agent solution B; a stop solution; and aconcentrated washing liquid. The invention relates to the technical field of diabetic nephropathy detection. The detection method is simple to operate, is less affected by metabolic disorders and hemodynamics, can detect diabetic nephropathy in the I phase, has extremely high sensitivity, and has great significance for clinical early diagnosis and discovery of diabetes.

The present invention discloses a western medicine for treating type II diabetes. Active ingredients of the western medicine comprise the following raw materials in mass percentages: 25-35% of a DPP4inhibitor, 30-40% of a SGLT2 inhibitor and 25-45% of gliquidone. The DPP4 inhibitor, SGLT2 inhibitor and gliquidone are compounded, blood sugar level is significantly reduced, and besides, the compounded medicine can effectively relieve symptoms and pathological phenotypes of diabetic nephropathy and reduce production of urine proteins in urine of patients.

The invention provides a pharmaceutical composition for improving inflammation and oxidative stress reaction. The composition contains isoglycyrrhizin. The invention further provides use of the isoglycyrrhizin in preparation of a drug for treating chronic inflammatory diseases and oxidative stress injury diseases and application of the isoglycyrrhizin in preparation of a drug for treating diabeticnephropathy. The isoliquiritin has no toxic and side effects in treating the diabetic nephropathy, is low in cost and high in combined drug administration safety, and contributes to delaying exacerbation.

The invention discloses an application of a traditional Chinese medicine composition in preparation of drugs for treating diabetes and diabetic nephropathy. The traditional Chinese medicine composition is prepared from radix astragali, fructus lycii, rhizoma dioscoreae, semen coicis, radix scrophularise, radix glehniae, herba ecliptae, dried human placenta, cortex eucommiae, radix notoginseng, herba leonuri, leeches, cicada ecdysis, semen plantaginis and radix achyranthis bidentatae. According to the application, proven by experimental researches, the traditional Chinese medicine composition has a very good effect of reducing fasting blood-glucose of rats suffering from the diabetic nephropathy, and the content of blood serum creatinine, urea nitrogen, kidney index and urinary protein in the rats suffering from the diabetic nephropathy can be remarkably lowered. Meanwhile, the traditional Chinese medicine composition has a very good effect of preventing renal tubular epithelial cells from fibrosis. Novel pharmaceutical preparations for clinical indications can be developed.

The invention discloses an application of annona squamosa seed total lactones and annona squamosa pivalolactone monomeric compounds thereof to preparation of medicines for controlling diabetes and diabetic nephropathy thereof. Through massive experimental selection, results show that the annona squamosa seed total lactones and the annona squamosa pivalolactone monomeric compounds thereof have theefficacy of reducing fasting blood sugar of rats suffering from diabetic nephropathy, the content of serum creatinine, the content of urea nitrogen and the content of urine protein of the rats suffering from the diabetic nephropathy can be notably reduced, and the annona squamosa seed total lactones and the annona squamosa pivalolactone monomeric compounds thereof have good effects of reducing blood sugar and protecting the kidney.